Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2007

View Archived Issues

AC-220 well tolerated in phase I acute myeloid leukemia study

Btk inhibition with PCI-32765 evaluated in mouse lymphoma models

Adjunctive N-acetyl cysteine beneficial in schizophrenia patients

University of Montana reports new imaging agents for positron emission tomography (PET)

Advances in HIV treatment disclosed in recent patents

Researchers find that component in male semen enhances HIV infection

GSK completes acquisition of Reliant and obtains U.S. and Porto Rican rights to Lovaza

SK-PC-B70M reverses scopolamine-induced memory deficits in vivo

Kalypsys initiates phase IIa clinical trial of KD-7040 for postherpetic neuralgia

Array BioPharma reports results from phase II study of AZD-6244 in advanced melanoma

Ambrx enters collaboration with Merck & Co. to develop FGF-21 follow-up type 2 diabetes drug

Recent Dainippon and Roche patents describe new treatment options for cardiovascular diseases

FDA grants orphan drug status to Anthera's A-001 for acute chest syndrome in sickle cell disease

BioCancell and VBDC partner to perform clinical trial of BC-819 in pancreatic cancer

NXL-105 selected for preclinical development

Otsuka acquires rights to IV Busulfex from PDL BioPharma

First patient dosed in phase III program for bapineuzumab in Alzheimer's

E.U. Commission approves first-in-class integrase inhibitor Isentress for HIV therapy

FDA grants IND authorization to Athersys for phase I clinical trial of MultiStem for AMI

Elan and Transition Therapeutics initiate dosing in phase II clinical study of ELND-005 for AD

Amicus reports positive results from four phase II clinical trials of Amigal for Fabry disease

Human Genome Sciences acquires rights to Aegera's AEG-40826 for cancer

Bayer discontinues marketing of Viadur; Vantas now only 12-month implant for prostate cancer in U.S.

ISTA submits NDA to FDA for Xibrom for inflammation, pain and photophobia

Millennium submits supplemental NDA to FDA for Velcade for multiple myeloma

FDA accepts and designates for priority review Jerini's NDA for icatibant for HAE

European Commission grants marketing authorization to Abbott's Humira for psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...